News and Events

News

All categories

Earnings

Press Release

All years

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

December 9, 2024

Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

December 9, 2024

Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients

December 8, 2024

Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)

December 5, 2024

Affimed Reports Third Quarter 2024 Financial Results & Business Update

November 14, 2024

Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024

November 6, 2024

Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma

November 5, 2024

Affimed to Present at the Cantor Global Healthcare Conference 2024

September 10, 2024

Affimed Reports Second Quarter 2024 Financial Results & Business Update

September 5, 2024

Affimed Appoints Shawn M. Leland as Chief Executive Officer

September 3, 2024

Events

All

Scientific

Investors

There are no events planned at the moment.

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients

Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)

Affimed Reports Third Quarter 2024 Financial Results & Business Update

Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024

Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma

Affimed to Present at the Cantor Global Healthcare Conference 2024

Affimed Reports Second Quarter 2024 Financial Results & Business Update

Affimed Appoints Shawn M. Leland as Chief Executive Officer

Events